Pritelivir (AIC316) - The perfect solution for resistant HSV infections at immunocompromised patients.

 

Pritelivir is a small molecule solution with a new mechanism of action that can efficiently treat HSV infections at patients that are resistant to acyclovir. Being a niche product and focusing on immunocompromised patients (Stem cell and solid organ transplant patients, HIV and cancer patients) Pritelivir can efficiently treat even severe outbreaks that significantly decrease quality of life and can be even life threatening.

Based on the high unmet medical need and interim analysis of Phase II clinical trial in June 2020 Pritelivir received a Breakthrough Therapy Designation from FDA. Currently Phase III study clinical trial for Pritelivir is under preparation.

AiCuris is looking for commercialization partners for Pritelivir in US and other markets.


Interested in learning more about this unique solution? Please contact: business(at)aicuris.com

If you have further questions regarding partnering of our projects please contact:

 
 
Dr. Igor Orshanskiy
Associate Director
Business Development &
Alliance Management
 
AiCuris Anti-infective Cures GmbH
Friedrich-Ebert-Str. 475
42117 Wuppertal
 
Phone: +49 (0)202 317 63 - 0
Fax: +49 (0)202 317 63 - 1177
E-Mail: business@aicuris.com